Antiemetic effect of ondansetron versus metoclopramide in nauseous isolated head trauma patients: a double-blind randomized clinical trial by Alimohammadi, Hossein et al.
FRONTIERS IN EMERGENCY MEDICINE. In Press Ali mohammadi et al .
ORIGINAL ARTICLE DOI: XXX
Antiemetic effect of ondansetron versus metoclopramide
in nauseous isolated head trauma patients: a double-blind
randomized clinical trial
Hossein Alimohammadi1, Hossein Partovinezhad2*, Ehsan Aliniagerdroudbari3, Sepideh Babaniamansour4,
Effat Partovinezhad2, Majid Shojaee1
1. Department of Emergency Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2. Department of Emergency Medicine, Ayatollah Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.
3. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4. School of Medicine, Islamic Azad University of Tehran Medical Sciences, Tehran, Iran.
*Corresponding author: Hossein Partovinezhad; Email: dr.partovinezhad@zums.ac.ir
Published online: 2021-01-20
Abstract: Objective: As nausea is one of the most common annoying symptoms in isolated head trauma (IHT) and needs
timely management to prevent further adverse outcomes, this study was performed to compare ondansetron
and metoclopramide as therapeutic agents in nauseous IHT.
Methods: This study was a double-blind clinical trial. Participants were patients visiting the ED with the chief
complaint of nauseous IHT event. Group A received 10mg/2ml of metoclopramide and group B 4mg/2ml of on-
dansetron through slow intravenous (IV) injection. The primary outcome was the severity of nausea 20 minutes
after the intervention based on the visual analogue scale (VAS) score.
Results: A total of 130 patients participated in the study (65 in each group). The mean age was 30.5±20.5 years,
and 73.1% of the participants were male. The decrease in the mean nausea severity scores was statistically signif-
icant in both group A (78.3±9.7 before vs. 29.8±16.8 mm after the intervention; P < 0.001) and group B (78.5±11.1
vs. 27.8±13.9 mm; P < 0.001). There was no significant difference between the mean nausea severity scores of
groups A and B before the intervention (P = 0.93) or after it (P = 0.65). The decrease in the severity score of nau-
sea was 48.5 mm in group A and 50.6 mm in group B, with no significant difference between the two groups (P =
0.63).
Conclusion: Both Ondansetron and metoclopramide significantly reduced the severity of nausea in patients
with mild IHT visiting ED but no treatment arm was superior. Both drugs showed good safety profiles.
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1. Introduction
Isolated head trauma (IHT) is one of the most important and
common types of traumas seen in patients visiting the emer-
gency department (ED) (1, 2). Head injury occurs in 22.1
per 1000 persons in a year (3) and accounts for one-third of
deaths caused by trauma and 16000 deaths daily. It is a lead-
ing cause of disability worldwide (2). Developing countries
like Iran experience a high incidence of IHT due to the high
prevalence of accidents as its most common mechanism (2,
4, 5). A range of symptoms and signs are observed in pa-
tients with IHT including headache, nausea, vertigo, and loss
of consciousness. Nausea in IHT is one of the most common
annoying symptoms and needs timely management to pre-
vent further adverse outcomes such as aspiration or rise of
intracranial pressure (1, 6). The incidence of nauseous IHT
has been reported between 25% to 28% in different studies
and has become one of the important challenges in the ED
(3, 7). Ondansetron, a serotonin receptor antagonist, and
metoclopramide, a dopamine receptor antagonist, are widely
used in the ED for the management of this condition. Dif-
ferences in the onset of actions, effective dosages, and side
effects make it difficult to choose the best antiemetic drug
in patients with various causes of nausea and different clin-
ical conditions (1, 8-12). Past studies mostly compared the
antiemetic effects of ondansetron and metoclopramide in
preventing or treating nausea related to chemotherapy and
gastroenteritis and post-operative nausea (1, 8, 13-18). Be-
cause of the limited number of studies, there is no consen-
sus among physicians regarding the best antiemetic drug for
patients with IHT. Therefore, this study was performed to
compare ondansetron and metoclopramide as therapeutic
agents for the management of patients with nauseous IHT.
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2. Methods
2.1. Trial design
This study was a double-blind clinical trial conducted at
Imam Hossein Hospital affiliated with Shahid Beheshti
University of Medical Sciences, in Tehran, Iran, between
September 2016 and February 2017. The executive pro-
tocol of the study was approved by the ethics commit-
tee of Shahid Beheshti University of Medical Sciences
(IR.SBMU.SM.REC.1394.209) and registered in the Iranian
Registry of Clinical Trials (IRCT2017010231731N1). The
study was conducted in accordance with the Declaration of
Helsinki (seventh revision 2013). Written informed consent
was obtained from all patients before they participated in the
study. Performing this study did not impose additional costs
on the participants.
2.2. Participants
Participants in the study were patients visiting the ED with
the chief complaint of nauseous IHT event. The included pa-
tients were aged ≥ 15 years, had a score of at least 13 on the
Glasgow coma scale (GCS) (19), and had been assigned to the
triage level 3 or below on admission (20). The exclusion crite-
ria were as follows: GCS score less than 13, triage level of 1 or
2, breastfeeding, pregnancy, alcohol use, current chemother-
apy or radiotherapy, hemodynamic instability, neurological
deficits, restless legs syndrome, known allergy to metoclo-
pramide or ondansetron, use of illicit drugs or antiemetic
medication within eight hours before the intervention, and
receiving IV fluids during the admission. Those who could
not complete the study were also excluded.
All patients visiting the ED with IHT underwent primary as-
sessment, including evaluation of the airway status and head
and neck condition and measurement of vital signs and level
of consciousness based on GCS. A checklist, including items
regarding age, gender, weight, mechanism of trauma (as-
sault, motor vehicle collision, and fall), and accompanying
symptoms (vertigo, headache, and blurred vision), was filled
in for the participants.
2.3. Interventions
Group A received 10mg/2ml of metoclopramide and group B
received 4m/2ml of ondansetron, through slow IV injection
(1, 21). Ondansetron and metoclopramide were manufac-
tured by Tehran Chemistry Company, Iran. A pharmacolo-
gist blinded to the study process provided the drugs, filled
the syringes, and put number codes on them. The number
code did not reveal which drug the syringe contained. The
prepared drugs were kept in a fridge in the ED. A resident
of emergency medicine was in charge of patient assessment
and drug administration. The nausea severity score of the
patient was determined before and 20 minutes after the in-
tervention. If the nausea severity score did not show a sig-
nificant decrease (at least 20 mm) after 20 minutes, 4mg on-
dansetron was administered as the rescue dose. The main
researcher was the only person who knew about treatment
arms and the content of syringes used in drug administra-
tion. All other people involved in the study, including pa-
tients, nurses, and other researchers, were blinded to the as-
sessments unless extrapyramidal side effects, such as flush-
ing, dystonia, and drowsiness, occurred (1).
2.4. Primary assessment
The visual analogue scale (VAS) is a standard self-report psy-
chometric scale. The patient marks the severity of nausea
along a straight-line scale from zero to 100 mm. Scores of
zero and 100 refer to the lowest and highest severity of nau-
sea, respectively. Scores of less than 50mm, 50mm to 70mm,
70mm and higher than 70 mm denote mild, moderate, and
severe degrees of nausea, respectively (22).
2.5. Outcomes
The primary outcome was the severity of nausea, 20 minutes
after the intervention, based on VAS. The requirement for a
rescue dose and reported drug side effects, such as extrapyra-
midal side effects, were the secondary outcomes.
2.6. Sample size
Using the formula below, the sample size was calculated as
at least 65 subjects in each arm of the study, with α=0.05, a
power of 80%, a mean difference of 5, and a standard devia-
tion (SD) of 14 in the nausea severity score of ondansetron
and metoclopramide groups. The sampling of eligible par-




2.7. Randomization and blinding
Permuted block randomization was performed to balance
the number of subjects assigned to each group, and pa-
tients were randomly assigned to blocks. Using a computer-
generated table, the project supervisor randomly allocated
letters A or B to the patients and assigned them to respective
groups to receive the coded drugs.
2.8. Statistical analysis
SPSS Version 21.0 (SPSS Inc., Chicago, IL, USA) was used to
analyze the data. The normality of distribution was assessed
using the Shapiro-Wilks test and graphical approach. The
quantitative variables were described using mean ± SD and
qualitative variables using frequency and percentage. The
independent sample t-test was used to assess the difference
between the means of the two groups and the paired sample
t-test to assess the difference between the means before and
after the intervention in each group. The difference in qual-
itative variables was assessed based on the Chi-square and
Fisher’s exact tests (for normal variables) or Mann Whitney U
test (for non-normal variables). A P < 0.05 was considered as
statistically significant.
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Figure 1 CONSORT flow diagram of the trial
3. Results
A total of 130 patients participated in the study (65 in each
group). Figure 1 shows the CONSORT flowchart for the
study patients. The mean age of the subjects was 30.5±20.5
years and 73.1% of them were male. The frequencies of
accompanying symptoms, including vertigo, headache, and
blurred vision, were 51(39.2%), 81(62.3%), and 17(13.1%), re-
spectively. The frequencies of IHT mechanisms, including
assault, motor-vehicle-collision, and falls, were 42(32.3%),
61(46.9%), and 27(20.8%), respectively. Before the interven-
tion, the nausea severity scores of the patients were in the
range of 60 mm to 100 mm, with 70 mm being the most fre-
quent score reported by the patients (34.6%). However, 10
mm was the most frequent score in the secondary VAS as-
sessment after the intervention (34.6%) (Figure 2).
The mean nausea severity scores for all patients before and
after the intervention were 78.4±10.4 mm and 28.8±15.3 mm,
respectively, and their difference was statistically significant
(P < 0.001).
The mean nausea severity scores of group A before and af-
ter the intervention were 78.3±9.7 mm and 29.8±16.8 mm, re-
spectively, and the decrease in the score was statistically sig-
nificant (P < 0.001).
The mean nausea severity scores of group B before and after
the intervention were 78.5±11.1 mm and 27.8±13.9 mm, re-
spectively, and the decrease in the score was statistically sig-
nificant (P < 0.001).
The mean severity scores of groups A and B before the in-
tervention were not significantly different (P=0.93). Likewise,
there was no significant difference between the mean nau-
sea severity scores of the two groups after the intervention (P
= 0.65) (Figure 3). Furthermore, the decrease in the severity
scores of groups A and B were 48.5 mm and 50.6 mm, respec-
tively, with no significant difference between the two groups
in this regard (P = 0.63).
In both treatment arms, the requirement for a rescue dose
was less frequent than non-requirement. Furthermore, there
was no significant difference between treatment arms in
terms of requirement and non-requirement for a rescue dose
(P= 0.641) (Table 1). Finally, none of the participants reported
any side effects.
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Figure 2 Distribution of the severity score of nausea and vomiting among treatment groups based on primary and secondary VAS scores
Figure 3 Boxplot of the severity score of nausea and vomiting among treatment groups based on primary and secondary VAS score
Table 1 The number of patients in each treatment arm according to the requirement for a rescue dose
Treatment arm Not required Required P-value*
Number (%)
A: Metoclopramide 53 (81.5) 12 (18.5) 0.641
B: Ondansetron 55 (85.6) 10 (15.4)
*The p-value refers to the difference between treatment arms in terms of requirement and non-requirement for a rescue dose
4. Discussion
Treating nausea is one of the most important challenges in
the management of IHT patients visiting the ED. In this study,
the antiemetic effect of ondansetron was compared to meto-
clopramide in patients with mild IHT. Most patients had nau-
sea of moderate severity before the intervention, and both
ondansetron and metoclopramide showed a significant ef-
fect in reducing its severity. There was no significant differ-
ence between the two treatment arms in terms of the drug
effectiveness in reducing nausea severity and the frequency
of requirement for a rescue dose.
Consistent with the results of the present study, Zamani et al.
compared ondansetron and metoclopramide in 120 patients
with mild IHT in Iran and reported that the severity of nau-
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sea was significantly reduced by both drugs and the efficacy
of the drugs showed no significant difference (1).
Various studies have compared the antiemetic effect of on-
dansetron and metoclopramide in patients with other mech-
anisms and causes of nausea. One study compared the
effects of dexamethasone, in combination with metoclo-
pramide or ondansetron, on preventing nausea after laparo-
scopic surgery and showed no significant difference between
the two treatment arms (16). Abas et al. compared the effi-
cacy of ondansetron and metoclopramide in the treatment of
hyperemesis gravidarum, and the results showed no signifi-
cant difference between the two drugs (9).
In contrast to our findings, some studies have shown signifi-
cant differences in the antiemetic effects of ondansetron and
metoclopramide. Dalhat et al. compared the preventive ef-
fect of ondansetron and metoclopramide against nausea in
66 patients after laparoscopic surgery. They reported that
ondansetron was superior to metoclopramide in preventing
post-operative nausea (8). In the study of Dalhat, et al., the
dosage of ondansetron and metoclopramide was similar to
that in the present study. The difference in the results of that
study and the present study can be related to the fact that dif-
ferent groups were investigated in the two studies and Dalhat
et al. studied the preventive, rather than therapeutic effects,
of the drugs.
Moreover, several studies have questioned the antiemetic ef-
fect of ondansetron and metoclopramide as they did not find
a significant difference between either ondansetron or meto-
clopramide and placebo in terms of antiemetic effects. These
studies reported that supportive treatment and hydration of
patients were as effective as antiemetic medication (17, 23,
24). In two studies reviewed by Patanwala et al., metoclo-
pramide was not more effective than placebo (21). Pitts et al.
conducted a study of 270 patients visiting the ED with nausea
from any cause. They administered ondansetron in a dose
similar to our study and metoclopramide in a dose twice that
used in the present study and placebo intravenously to dif-
ferent groups of patients and measured the severity of nau-
sea based on the VAS 35 minutes later. The results showed
no significant difference between the three groups in treat-
ing nausea, and the metoclopramide group had the lowest
frequency of the requirement for a rescue dose (25). The dif-
ference in results might be related to the severity of nausea
before the intervention in our study, the number of partici-
pants, cause of nausea, age groups, and dosage of drugs.
In the present study, ondansetron and metoclopramide had
no side effects and no significant difference in terms of the
frequency of requirement for a rescue dose. These find-
ings are in line with the results of some earlier studies (26,
27); however, Zamani et al. stated that both drugs had sev-
eral side effects and caused drowsiness and anxiety and also
that the required rescue dose was significantly more frequent
among those receiving metoclopramide (1). Khatereh et al.
showed that the required rescue dose was more frequent in
metoclopramide (20%) compared to ondansetron (0%) (15).
Abas reported that the frequency of headache, diarrhea, pal-
pitation, and sleep issues showed no significant difference
in those treated with ondansetron and metoclopramide but
dry mouth mostly occurred in the metoclopramide arm (9).
The difference between the results of these studies and the
present study might be related to differences in the study
population, dosage and way of administration of the drugs,
time of side effects evaluation, mechanism and cause of nau-
sea, and supportive treatments provided.
5. Limitations
Conducting a single-center study and using the convenience
method for sampling increased the risk of selection bias.
Given the mental and physical stressful conditions of pa-
tients at the time of the first measurements of nausea sever-
ity, the high scores might be influenced by bias. On the
other hand, the significant reduction of nausea severity
in the second measurement might be related not only to
antiemetic medication but also to changes in patients’ con-
ditions. Therefore, it is highly recommended to assess the
placebo effect and patients’ distress before and after the in-
tervention.
6. Conclusion
Both ondansetron and metoclopramide significantly re-
duced the severity of nausea in patients with mild IHT visit-
ing the ED; however, neither of the treatment arms was supe-
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